High Times
Home > Boards > US OTC > Biotechs >

ImmunoCellular Therapeutics Ltd. (IMUC)

Add IMUC Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 10/19/2018 3:52:09 PM - Followers: 185 - Board type: Free - Posts Today: 0




ImmunoCellular Therapeutics continues to make significant progress in meeting important goals and positioning the company for success. We believe that our cancer vaccine platform has the potential to be transformative in the treatment of cancer, and to create value for all our stakeholders. Our goal is to build ImmunoCellular into a leading, independent commercial-stage cancer immunotherapy company.

Our dendritic cell (DC) vaccine technology and advanced manufacturing offer several advantages over earlier-generation cellular immunotherapies:

- Matured DCs secrete IL12, which is critical for stimulating T cell killing of cancer cells.
More than 80% of the final manufactured product consists of matured DCs.

- Unlike other cell-based vaccines, our DCs target multiple antigens, thus increasing the likelihood of effective treatment.

- Advanced manufacturing enables production of at least 20 doses of vaccine from a single apheresis (blood collection); thus patients do not need to undergo additional apheresis procedures.

- Compared to the only approved cell-based immunotherapy, our DC vaccines can be manufactured at a significantly reduced cost.

- Ability to freeze and store vaccine for months or years eliminates the need to administer to the patient shortly after manufacture.
- Intradermal administration route reduces the time and inconvenience of intravenous infusion for both patient and physician.

Company Information:

21900 Burbank, 3rd Floor
Woodland Hills, CA 91367

Phone: 818-992-2907



Technologies:   http://imuc.com/technology/

Press Releases:   http://imuc.com/press/





Transfer Agent:

U.S. Stock Transfer Corp.
Suite 200
Glendale, CA 91204-2991

 Investor Relations:

Gary Nash, CEOcast, Inc.

Tel: (212)732-4300
Email: IR@imuc.com







ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell vaccine targeting CD133; ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer killing T-cells.

Announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma (GBM). This agreement with PharmaCell, a leading European contract manufacturing organization focuses on the production of human cell therapy products, and is designed to enable ImmunoCellular to access phase 3 supplies of ICT-107, manufactured with ImmunoCellular's commercial-ready production process. ImmunoCellular intends to initiate a Phase 3 registrational program for ICT-107 in the US and in Europe in 2015

>>> What these CANCER vaccines could be worth


Investor Presentation -> http://files.shareholder.com/downloads/AMDA-1HS8HT/61684022x0x652321/5FD13B20-8F93-44CE-994E-D5515E5F30FC/IMI_Corporate_Overview.pdf 





High Times
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IMUC News: Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ... 10/18/2018 01:04:47 PM
IMUC News: Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ... 10/18/2018 01:04:07 PM
IMUC News: Current Report Filing (8-k) 10/17/2018 06:33:06 AM
IMUC News: ImmunoCellular Announces Receipt of Notice of Noncompliance with The NYSE American Continued Listing Standards 10/17/2018 06:00:00 AM
IMUC News: Current Report Filing (8-k) 10/15/2018 04:36:33 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#5295   Why are there no charts for this ? looking 4 a win 10/19/18 03:52:08 PM
#5294   The blatant manipulation we are seeing here is G-Schmoney 10/19/18 10:14:07 AM
#5293   The blatant manipulation we are seeing here is G-Schmoney 10/19/18 10:13:14 AM
#5292   IMUC only 50M A/S sitting at .04, the G-Schmoney 10/19/18 01:28:50 AM
#5291   IMUC held by 24 Insitutional holders! https://www.nasdaq.com/symbol/i G-Schmoney 10/19/18 01:13:37 AM
#5290   IMUC looks like it may have bottomed out, G-Schmoney 10/19/18 01:08:43 AM
#5289   Thank the Lord I sold this pig back UFO 10/17/18 09:00:22 AM
#5288   IMUC delisted from the NYSE to the OTC. Renee 10/16/18 06:43:42 PM
#5287   OUCH! 420man 10/15/18 07:00:01 PM
#5286   Close to 3+ yrs later not surprisingly IMUC maverick_1 10/15/18 05:13:55 PM
#5285   Form 8-K ImmunoCellular Therapeut For: May 14 PyschoNoobStock 05/15/18 11:44:40 PM
#5284   BRIEF-ImmunoCellular Therapeutics Q1 Loss Per Share $0.02 PyschoNoobStock 05/15/18 11:44:16 PM
#5283   Form 10-Q ImmunoCellular Therapeut For: Mar 31 PyschoNoobStock 05/15/18 11:43:39 PM
#5282   ImmunoCellular 1Q R&D Expenses $290,616 >IMUC PyschoNoobStock 05/15/18 11:43:20 PM
#5281   ImmunoCellular 1Q Loss $1.02M >IMUC PyschoNoobStock 05/15/18 11:42:59 PM
#5280   ImmunoCellular 1Q Rev $0.00 >IMUC PyschoNoobStock 05/15/18 11:42:37 PM
#5279   ImmunoCellular Therapeutics Announces First Quarter 2018 Financial Results-Co PyschoNoobStock 05/15/18 11:42:14 PM
#5278   ImmunoCellular 1Q Loss/Shr 2c >IMUC PyschoNoobStock 05/15/18 11:40:56 PM
#5277   Medigene in for up to $1.5 bln under PyschoNoobStock 05/14/18 12:09:45 PM
#5276   Up .2812. Green baby! PyschoNoobStock 05/09/18 03:09:17 PM
#5275   WOW! Inverse SKS chart formation in the works sindram 05/05/18 05:21:03 AM
#5274   I dont now.. Now we up .2803! PyschoNoobStock 05/04/18 10:37:56 AM
#5273   Bunch of buys at the end of day...are JJAAMMAANN 05/02/18 07:10:32 PM
#5272   Weeee.. UP .2725!! PyschoNoobStock 05/02/18 12:16:05 PM
#5271   Renaissance Technologies have 500K+ shares here. Not too TheAnnointedOne 04/23/18 09:56:30 PM
#5270   So we have one of the largest and TheAnnointedOne 04/23/18 07:38:42 PM
#5269   I have no confidence. People calling for a Lion33 04/23/18 11:32:07 AM
#5268   Still here.. More good news will come soon.. PyschoNoobStock 04/23/18 08:50:55 AM
#5267   Nice! I think I’ll be setting mines up TheAnnointedOne 04/21/18 06:55:21 PM
#5266   I'm here with you Sam. JJAAMMAANN 04/21/18 01:31:09 AM
#5265   12 month forecast. Low: $5 High: $80 I’ll TheAnnointedOne 04/20/18 08:53:26 PM
#5264   Is it just me and the hedgies left? TheAnnointedOne 04/20/18 02:37:42 PM
#5263   Looks like this will remain stagnant until the TheAnnointedOne 04/20/18 12:06:06 PM
#5262   Once results come in this will rebound hard. TheAnnointedOne 04/19/18 07:33:29 PM
#5261   Holding solid in this range. Accumulation happening... TheAnnointedOne 04/19/18 04:21:25 PM
#5260   I like that forecast. TheAnnointedOne 04/18/18 02:27:07 PM
#5259   Going higher! PyschoNoobStock 04/18/18 01:21:16 PM
#5258   Weeee!!!!!!! PyschoNoobStock 04/18/18 01:00:43 PM
#5257   Reversal? Dmwcrash 04/18/18 12:44:20 PM
#5256   Found this stock price forecast for IMUC, it nofortunateson2 04/14/18 05:38:22 PM
#5255   yeah, with this shorting nowadays, trading apps in Trompete 04/14/18 11:14:45 AM
#5254   Whenever clay trader appears expect it to return Hbpainter 04/14/18 05:28:23 AM
#5253   I’ve heard that before Lion33 04/12/18 05:47:45 PM
#5252   * * $IMUC Video Chart 04-12-18 * * ClayTrader 04/12/18 05:02:33 PM
#5251   Sorry guys but I jumped ship at the top. Dmwcrash 04/12/18 11:45:33 AM
#5250   Anything under .30 is a steal Joecanada13 04/12/18 10:19:50 AM
#5249   Up .32! PyschoNoobStock 04/12/18 09:53:10 AM
#5248   BIG NEWS!! PyschoNoobStock 04/12/18 09:49:40 AM
#5247   BIG NEWS!!! PyschoNoobStock 04/12/18 09:49:16 AM
#5246   ImmunoCellular Therapeutics Successfully Transfers T Cell Receptor Genetic PyschoNoobStock 04/12/18 09:48:08 AM